Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET
IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025.
Title: |
Mdxhealth Presents First Quarter 2025 Financial Results and Corporate Update Conference Call and Webcast |
Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
Date: | May 14, 2025 |
Time: | 4:30pm ET/ 22:30 CET |
Conference Call Dial-in Details: | United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064 |
Conference ID: | 10199102 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1716341&tp_key=092e4b795e |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
MDxHealth info@mdxhealth.com |
|
LifeSci Advisors (IR & PR) US: +1 949 271 9223 ir@mdxhealth.com |
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。